The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 26700752 |
46 |
Novel Small Molecule Inhibitors of Choline Kinase Identified by Fragment-Based Drug Discovery. |
Ariad Pharmaceuticals |
| 24387243 |
4 |
Discovery of a new binding site on human choline kinasea1: design, synthesis, crystallographic studies, and biological evaluation of asymmetrical bispyridinium derivatives. |
Universidad De Granada |
| 21996467 |
17 |
Synthesis and biological activity of new bispyridinium salts of 4,4'-bispyridyl-5,5'-perfluoroalkyl-2,2'-bisoxazoles. |
Universidad Europea De Madrid |
| 21417225 |
116 |
Homodimeric bis-quaternary heterocyclic ammonium salts as potent acetyl- and butyrylcholinesterase inhibitors: a systematic investigation of the influence of linker and cationic heads over affinity and selectivity. |
Universidad De Granada |
| 15857141 |
41 |
Symmetrical bis-quinolinium compounds: new human choline kinase inhibitors with antiproliferative activity against the HT-29 cell line. |
Universidad De Granada |
| 15481981 |
25 |
Influence of the linker in bispyridium compounds on the inhibition of human choline kinase. |
Universidad De Grenada |
| 12904080 |
5 |
Bispyridinium cyclophanes: novel templates for human choline kinase inhibitors. |
Universidad De Granada |
| 27429068 |
54 |
Evolution of a Novel, Orally Bioavailable Series of PI3K? Inhibitors from an Inhaled Lead for the Treatment of Respiratory Disease. |
Glaxosmithkline R&D |
| 10782682 |
10 |
QSAR of 1,1'-(1,2-ethylenebisbenzyl)bis(4-substitutedpyridinium) dibromides as choline kinase inhibitors: a different approach for antiproliferative drug design. |
Granada |
| 24976941 |
2 |
Design of symmetrical and nonsymmetrical |
Imperial College |
| 30082069 |
359 |
ROCK inhibitors 3: Design, synthesis and structure-activity relationships of 7-azaindole-based Rho kinase (ROCK) inhibitors. |
Vertex Pharmaceuticals |
| 29945794 |
193 |
ROCK inhibitors 2. Improving potency, selectivity and solubility through the application of rationally designed solubilizing groups. |
Vertex Pharmaceuticals |
| 29880399 |
17 |
1,2-Diphenoxiethane salts as potent antiplasmodial agents. |
Universidad De Granada |
| 28347666 |
45 |
Discovery of a series of 8-(1-phenylpyrrolidin-2-yl)-6-carboxamide-2-morpholino-4H-chromen-4-one as PI3K?/? inhibitors for the treatment of PTEN-deficient tumours. |
Astrazeneca |
Search and Browse
